Ghostwriting - getting closer to the test tube
Dentists leafing through The Journal of the American Dental Association last May found a study concluding that a new drug called Bextra offered relief from one of their patients' worst nightmares -- the acute pain that follows dental surgery. Federal regulators had rejected that conclusion only six months before, leaving Bextra's marketers, Pharmacia and Pfizer, hard pressed to sell it as an advance over Celebrex, their earlier entry in a crowded market for pain drugs. The new study helped light a fire under Bextra. Madison Ave. Has Growing Role In the Business of Drug Research
Big Pharma and Madison Avenue
Omnicom Group - Home
Omnicom Group Inc. is an American global advertising, marketing and corporate communications holding company, headquartered in New York City. It is the world's top corporate media services conglomerate and one of the "Big Four" agency companies (alongside WPP, Interpublic and Publicis). The company oversees an international network of more than 1,500 agencies and provides services for over 5,000 clients in more than 100 countries. Omnicom's agencies provide marketing and communications services in the disciplines of advertising, customer relationship management (CRM), strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations (PR) and other specialty communications. Omnicom’s agency networks include BBDO, DDB Worldwide, TBWA Worldwide, Diversified Agency Services (DAS) and Omnicom Media Group (OMG). Omnicom Group
Interpublic Group: home
Interpublic Group of Companies The Interpublic Group of Companies, Inc. (IPG) (NYSE: IPG) is one of the big four global advertising holding companies (the others being Omnicom, WPP and Publicis). It is headquartered in New York City and is the parent company of advertising and marketing services agencies around the world. The company consists of three major networks: McCann Worldgroup, Lowe and Partners and Draftfcb. Its media agencies are bundled under the IPG Mediabrands entity. It also owns a number of specialty agencies, including public relations, sports marketing, talent representation and healthcare.
WPP plc is a British multinational advertising and public relations company with its main management office in London, United Kingdom, and its executive office in Dublin, Ireland. It is the world's largest advertising company by revenues, and employs around 162,000 people in 3,000 offices across 110 countries. It owns a number of advertising, public relations and market research networks, including Grey, Burson-Marsteller, Hill & Knowlton, JWT, Ogilvy Group, TNS, Young & Rubicam and Cohn & Wolfe. WPP has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has a secondary listing on NASDAQ. History WPP plc
Publicis Publicis Groupe was a French multinational advertising and public relations company, headquartered in Paris, France. Up to July 2013, it was one of the "Big Four" agency companies (alongside WPP, Interpublic and Omnicom). Publicis Groupe S.A. is presided by Maurice Lévy, and its agencies provide digital and traditional advertising, media services and marketing services (SAMS) to national and multinational clients. On 28 July 2013, it was announced that Publicis Groupe and Omnicom Group would merge to form Publicis Omnicom Group. Overview The company was founded by Marcel Bleustein-Blanchet in 1926. The company owned several full-service advertising groups that undertake a range of media activities: mobile and interactive online communication, television, magazines & newspapers, cinema and radio, outdoor.
Scirex - Premier Research
Bart Penders Annemiek Nelis Laboratory ethnographies have provided valuable insights in the workings of contemporary science and technology and about facts in the making. The Social Study of Corporate Science: A Research Manifesto
John Verbakel, Vice President Research and Development | Unilever
Prof Accuses Colleagues of Slanted Research By Paul Basken A University of Pennsylvania psychiatry professor has accused his department chairman and four colleagues of publishing an article that was ghostwritten on behalf of a pharmaceutical company and made unsupported claims for one of its best-selling drugs. The medical-journal article, published in 2001, "was biased in its conclusions" and "made unsubstantiated efficacy claims and downplayed" negative side effects of the antidepressant drug Paxil, according to a complaint filed by lawyers for Jay D. Amsterdam, a professor of psychiatry at Penn. Dr.
Amsterdam, J.D., Newberg, A: Dopamine Transporter Density in Bipolar Type II and Unipolar Major Depressive Episode. Neuropsychobiology 55: 167-170, 2007. Michelson D, Adler L, Amsterdam JD, Dunner D, Nierenberg A, Reimherr F, Schatzberg Am Kelsey D, Williams D: Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double blind, placebo controlled study. Journal of Clinical Psychiatry 68: 582-587, 2007. Newberg AB, Amsterdam JD, Shults J: Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nuclear Medicine Communications 28(1): 3-6, 2007. Jay. D. Amsterdam
By Paul Basken Universities have been struggling for years with the problem of researchers who let industry-financed ghostwriters draft biased summaries of their work for publication in medical journals. They're now getting some blunt advice on how to stop it, including from perhaps the most qualified experts: the ghostwriters themselves. In a pair of articles published Tuesday by PLoS Medicine, two professional medical writers outlined changes that both universities and the journals could make. Universities Get Advice on How to Avoid Ghostwriting Scandals in Research Articles - Government
Being the Ghost in the Machine: A Medical Ghostwriter's Personal View
Helen Hayes Hospital | The Power of Rehabilitation
Linda Logdberg - Georgia Perimeter College [all campuses]
? Linda Logdberg ?
Dr Logdberg's webpage
Aug. 9, 2011 — Rather than ensure the proper attribution of authorship, rules set up by leading medical journals to define and credit authorship of published articles are exploited by the pharmaceutical industry in its attempt to conceal and misrepresent industry contributions to the literature. This is a perspective contained in an article by Alastair Matheson, a medical writer based in the UK and Canada, who argues in this week's PLoS Medicine that the current International Committee of Medical Journal Editors (ICMJE) authorship guidelines allow for industry to exaggerate the contribution of named academic authors and downplay that of commercial writers who are excluded from authorship but listed as contributors in the small print. Matheson contends that the ICMJE guidelines should be fundamentally revised and the concept of origination given comparable importance to authorship and contributorship. Authorship rules for medical journals flouted by pharma industry, experts say
How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be Revised
ICMJE: Uniform Requirements for Manuscripts Submitted to Biomedical Journals
Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Articles
Carrie Wolinetz (Dr_CarrieDale) sur Twitter
Medicijn op zoek naar een ziekte
Trouw: Wetenschappelijke fraude komt vaker voor
Harvard Medical School Professor Among Five Accused of Ghostwriting
Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey
NTvG: Onrechtmatig auteurschap nog steeds grootschalig probleem